Table 2.
Treatment characteristics
| Characteristic, n (%) | ACI | MTX | FAE | CyA | ALI | APR | ADA | ETA | INX | GOL | CER | UST | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of treatment courses | 205 | 220 | 96 | 70 | 53 | 35 | 69 | 62 | 32 | 12 | 8 | 42 | 31 |
| + PUVAa | 75 (36.6) | 31 (14.1) | 18 (18.8) | 0 (0.0) | 9 (17.0) | 6 (17.1) | 0 (0.0) | 6 (9.7) | 3 (9.4) | 0 (0.0) | 0 (0.0) | 1 (2.4) | 5 (16.1) |
| + MTXb | 0 (0.0) | NA | 0 (0.0) | 1 (1.4) | 0 (0.0) | 2 (5.7) | 21 (30.4) | 22 (35.5) | 20 (62.5) | 4 (33.3) | 1 (12.5) | 3 (7.1) | 2 (6.5) |
| + prednisolonea | 3 (1.5) | 16 (7.3) | 0 (0.0) | 2 (2.9) | 1 (1.9) | 5 (14.3) | 7 (10.1) | 8 (12.9) | 5 (15.6) | 2 (16.7) | 3 (37.5) | 0 (0.0) | 2 (6.5) |
| Dosage 1b | 60 (29.3) | 15 (6.8) | 10 (10.4) | 14 (20.0) | 3 (5.7) | 34 (97.1) | 64 (92.8) | 56 (90.3) | 25 (78.1) | 11 (91.7) | 8 (50.0) | 36 (85.7) | 30 (96.8) |
| Dosage 2b | 115 (56.1) | 140 (63.6) | 20 (20.8) | 40 (57.1) | 5 (9.4) | 1 (2.9) | 5 (7.3) | 6 (9.7) | 7 (21.9) | 1 (8.3) | 8 (50.0) | 6 (14.3) | 1 (3.2) |
| Dosage 3b | 2 (1.0) | 38 (17.3) | 37 (38.5) | 7 (10.0) | 37 (69.8) | NA | NA | NA | NA | NA | NA | NA | NA |
| 1st syst. treatment | 118 (57.6) | 118 (53.6) | 39 (40.6) | 18 (25.7) | 21 (39.6) | 1 (2.9) | 4 (5.8) | 2 (4.1) | 2 (6.3) | 1 (8.3) | 1 (12.5) | 0 (0.0) | 5 (16.1) |
| 2nd syst. treatment | 51 (24.9) | 62 (28.2) | 28 (29.2) | 21 (30.0) | 10 (18.9) | 11 (31.4) | 14 (20.3) | 13 (26.5) | 5 (15.6) | 3 (25.0) | 1 (12.5) | 4 (9.5) | 7 (22.6) |
| 3rd syst. treatment | 21 (10.2) | 24 (10.9) | 20 (20.8) | 15 (21.4) | 7 (13.2) | 5 (14.3) | 18 (26.1) | 8 (16.3) | 2 (6.3) | 7 (58.3) | 3 (37.5) | 4 (9.5) | 6 (19.4) |
| ≥ 4th syst. treatment | 15 (7.3) | 16 (7.3) | 9 (9.4) | 16 (22.9) | 15 (28.3) | 18 (51.4) | 33 (47.8) | 26 (53.1) | 23 (71.9) | 1 (8.3) | 3 (37.5) | 34 (81.0) | 13 (41.9) |
| 1st biological | NA | NA | NA | NA | NA | NA | 38 (55.1) | 41 (68.3) | 12 (37.5) | 2 (16.7) | 1 (12.5) | 20 (47.6) | 17 (54.8) |
| 2nd biological | NA | NA | NA | NA | NA | NA | 24 (34.8) | 11 (18.3) | 14 (43.8) | 3 (25.0) | 3 (37.5) | 9 (21.4) | 5 (16.1) |
| 3rd biological | NA | NA | NA | NA | NA | NA | 5 (7.3) | 5 (8.3) | 3 (9.4) | 5 (41.7) | 2 (25.0) | 10 (23.8) | 5 (16.1) |
| ≥ 4th biological | NA | NA | NA | NA | NA | NA | 2 (2.9) | 3 (5.0) | 3 (9.4) | 2 (16.7) | 2 (25.0) | 3 (7.1) | 4 (12.9) |
Number of treatment courses combined with topical PUVA, MTX, or prednisolone, respectively.
Non‐biologicals were categorized into 3 groups according to the dosage: acitretin <0.25/0.25‐0.5/>0.5 mg/kg body weight, MTX < 10/10–15/> 15 mg weekly, fumaric acid esters initial tablets/1–2 tablets/> 2 tablets, cyclosporine < 2.5/2.5–3.5/> 3.5 mg/kg body weight, alitretinoin ≤ 10/> 10–< 30/≥ 30 mg; biologicals and apremilast were categorized into standard maintenance dosage for psoriasis (Dosage 1) and any other regime (Dosage 2).
Abbr.: ACI, acitretin; MTX, methotrexate; FAE, fumaric acid esters; CyA, cyclosporine A; ALI, alitretinoin; APR, apremilast; ADA, adalimumab; ETA, etanercept; INX, infliximab; GOL, golimumab; CER, certolizumab pegol; UST, ustekinumab; SEC, secukinumab; syst. treatment, systemic treatment; NA, not applicable.